With the advent of innovative therapeutics such as glucagon-like peptide 1 to reduce obesity, new vehicles for identifying and engaging individuals with obesity and overweight status can be of substantial potential value in reaching patients in need. This evidence concerns the gene GCG and obesity disorder.